The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound

Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

[search][options]

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Nils Lycke

MIVAC

Institute of Biomedicine

University of Gothenburg

Gothenburg

Sweden

[email]@microbio.gu.se

Name/email consistency: high

[Claim this account]

Affiliations

MIVAC, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden. 2010
Department of Medical Microbiology and Immunology, University of Göteborg, Sweden. 1998 - 2005

References

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Lycke, N., Bemark, M. Mucosal. Immunol (2010) [Pubmed]
From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Lycke, N. Immunol. Lett. (2005) [Pubmed]
Targeted vaccine adjuvants based on modified cholera toxin. Lycke, N. Curr. Mol. Med. (2005) [Pubmed]
From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Lycke, N. Cell. Microbiol. (2004) [Pubmed]
ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Lycke, N. Ann. N. Y. Acad. Sci. (2004) [Pubmed]
The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses. Lycke, N. Curr. Opin. Mol. Ther. (2001) [Pubmed]
The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity. Lycke, N., Schön, K. Vaccine (2001) [Pubmed]
Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. Lycke, N., Erlandsson, L., Ekman, L., Schön, K., Leanderson, T. J. Immunol. (1999) [Pubmed]
Novel enabling technologies for vaccine development. 26-27 January 1999, Royal Society, London, UK. Lycke, N. IDrugs (1999) [Pubmed]
T cell and cytokine regulation of the IgA response. Lycke, N. Chem. Immunol. (1998) [Pubmed]